AKT can modulate the in vitro response of HNSCC cells to irreversible EGFR inhibitors

Epidermal growth factor receptor (EGFR) is overexpressed in up to 90% of head and neck squamous cell carcinoma (HNSCC) tumors. Cetuximab is the first targeted (anti-EGFR) therapy approved for the treatment of HNSCC patients. However, its efficacy is limited due to primary and secondary resistance, a...

Descripción completa

Detalles Bibliográficos
Autores principales: Silva-Oliveira, Renato José, Melendez, Matias, Martinho, Olga, Zanon, Maicon F., de Souza Viana, Luciano, Carvalho, André Lopes, Reis, Rui Manuel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5581110/
https://www.ncbi.nlm.nih.gov/pubmed/28881811
http://dx.doi.org/10.18632/oncotarget.18395

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5581110/
https://www.ncbi.nlm.nih.gov/pubmed/28881811
http://dx.doi.org/10.18632/oncotarget.18395

Ejemplares similares